<DOC>
	<DOCNO>NCT03004833</DOCNO>
	<brief_summary>The aim trial improve first-line treatment early unfavorable cHL introduction anti-PD-1 antibody Nivolumab truncate standard chemotherapy ( AVD ) . The primary objective show efficacy two experimental treatment strategy . Secondary objective evaluate efficacy , show safety feasibility perform correlative study .</brief_summary>
	<brief_title>Nivolumab AVD Early-stage Unfavorable Classical Hodgkin Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Histologically proven classical HL First diagnosis , previous treatment Age : 1860 year Stage I , IIA risk factor ad , IIB RF cd : 1. large mediastinal mass 2. extranodal lesion 3. elevate ESR 4 . ≥ 3 nodal area confirm central review . Composite lymphoma nodular lymphocyte predominant Hodgkin lymphoma ( NLPHL ) History malignancy ≤ 5 year Prior chemotherapy radiation therapy Concurrent disease preclude protocol treatment Pregnancy , lactation Noncompliance</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>